Medical insurance price of giritinib: latest reimbursement policy in 2025

Gilitinib is a targeted drug that specifically targets FLT3 mutations and is widely used to treat adult patients with relapsed or refractory acute myeloid leukemia (AML). FLT3 mutation is one of the most common genetic abnormalities in AML and is often closely related to disease progression and poor prognosis. By highly selectively inhibiting the abnormal activation of FLT3 kinase, giritinib blocks the proliferation signals of leukemia cells, effectively induces cancer cell apoptosis, improves the remission rate, and prolongs patient survival. Internationally, giritinib has been recommended by multiple authoritative guidelines as the first-line treatment for FLT3 mutation-positive relapsed or refractory AML, and it plays an important role in clinical practice.

The drug was developed by Japan's Astellas Pharmaceutical Company. The original version in China has been officially launched in China. The common packaging specification is40 mg × 21 tablets × 2 plates, and the price per box is more than RMB 20,000. Based on the recommended daily dosage of 120 mg, the monthly treatment cost may be close to 30,000 yuan, which is a heavy financial burden for most ordinary families. Especially for patients who need long-term maintenance treatment or are waiting for hematopoietic stem cell transplantation, the treatment cycle is long and the cost is high, making the sustainability of medication a real issue. At present, giritinib has not been included in the national medical insurance catalog, which means that patients cannot enjoy the reimbursement policy and must bear the full cost of the drug out of their own pocket.

Compared with the expensive original drugs, generic versions from countries such as Laos have become the choice that many patients pay attention to. Common Lao generic drugs currently on the market come from Laos Lucius, United Pharmaceuticals, ASEAN Pharmaceuticals and other manufacturers. The specifications are 40mg × 90 tablets. Each box sells for about 2,000 yuan. Converted based on the dosage, the price is only one-tenth or even lower than the original drug. These generic drugs are basically consistent with the original drugs in terms of drug ingredients, specifications, and dosage. In theory, they can achieve similar efficacy and blood concentration. Feedback from some users also shows that they have good clinical responses.

Reference materials:https://www.xospata.com/